At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 80 enrolled
Drug / intervention
COVID-19 Convalescent Plasmabiological
Likely dose
COVID-19 Convalescent Plasma 2 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.
In Brief
A Phase 1 clinical trial evaluating COVID-19 Convalescent Plasma for COVID-19. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedMay 2020
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedMay 21, 2020
Enrollment StartMay 13, 2020
Primary CompletionFeb 6, 2021
Study CompletionMar 8, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.1 years ago
Interventions
COVID-19 Convalescent Plasmabiological
2 units of COVID-19 convalescent plasma compatible with their blood type